McKenna, Claire; Maund, Emma; Sarowar, Muhammad; Fox, David - In: PharmacoEconomics 30 (2012) 1, pp. 35-46
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of dronedarone (Multaq®, Sanofi-Aventis Limited, UK) to submit evidence on the clinical and cost effectiveness of the anti-arrhythmic drug (AAD) for the treatment of atrial fibrillation (AF) and atrial...